Pegylated recombinant human hyaluronidase - Halozyme Therapeutics/Nektar Therapeutics
Alternative Names: PEG PH20; PEG rHuPH-20; pegvorhyaluronidase alpha; Pegylated hyaluronidase; PEGylated reombinant human hyaluronidase - Halozyme; Pegylated rHuPH20Latest Information Update: 15 Jun 2024
At a glance
- Originator Halozyme Therapeutics
- Developer Eisai Co Ltd; Genentech; Halozyme Therapeutics; Scripps Health; University of California at San Francisco
- Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
- Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 09 Nov 2023 Southwest Oncology Group in collaboration with Halozyme Therapeutics completes a phase Ib/II trial in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in USA (NCT01959139)
- 25 Sep 2020 Genentech terminates phase II trial in Pancreatic cancer (Neoadjuvant therapy, Combination therapy, First-line therapy) in USA due to loss of funding (IV) (NCT03979066)